Novo Nordisk loses share in Brazil as cheaper rivals gain market shareIn a recent update, Novo Nordisk is falling behind in the market in Brazil after its semaglutide patent expired, prompting a 3% contraction in third-quarter emerging market sales, while the drugmaker has held its ground in. ..



